Document:

Exhibit 10.5

 

NEITHER THE ISSUANCE AND SALE OF THE
SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE,
SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE REASONABLY ACCEPTABLE TO THE ISSUER), IN A GENERALLY
ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING
THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT
SECURED BY THE SECURITIES.

 

COMMON STOCK PURCHASE WARRANT

 

EVENT
CARDIO GROUP INC.

 

	Warrant Shares: 2,000,000	 	Initial Exercise Date: February 12, 2016

 

THIS COMMON STOCK
PURCHASE WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”) is entitled,
upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the
date hereof (the “Initial Exercise Date”) and on or prior to the close of business on February 28, 2019 (the
“Termination Date”) but not thereafter, to subscribe for and purchase from Event Cardio Group, Inc., a Nevada
corporation (the “Company”), up to two million (2,000,000) shares (the “Warrant Shares”)
of common stock, par value $.001 per share, of the Company (the “Common Stock”). The purchase price of one
share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section 1. Definitions.
Capitalized terms used herein without definition shall have the following meaning:

 

“Business
Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States or any
day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

     

     

    

Section 2.Exercise

 

a) Exercise.
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after
the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy of
the Notice of Exercise Form annexed hereto (or such other office or agency of the Company as it may designate by notice in writing
to the registered Holder at the address of such Holder appearing on the books of the Company); and, if the Exercise Price is to
be paid in cash, within three Trading Days of the date said Notice of Exercise is delivered to the Company, the Company shall
have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check
drawn on a United States bank. Alternatively, the Holder may pay the Exercise Price, in whole or in part, by surrender or delivery
to the Company of securities of the Company, including all or a portion of this Warrant in a “cashless exercise,”
having a fair market value, as determined below, on the date of the exercise equal to the portion of the purchase price being
so paid. If the Holder elects to exercise this Option, or a portion hereof, and to pay for the Common Stock by way of cashless
exercise (a “Cashless Exercise”), the Holder shall deliver the Exercise Notice duly executed by such
Holder or by such Holder’s duly authorized attorney, at the principal office of the Company, or at such other office or
agency as the Company may designate in writing prior to the date of such exercise, in which event the Company shall issue to the
Holder the number of shares computed according to the following equation:

 

 

where

 

X = the number of
shares of Common Stock to be issued to the Holder.

 

Y = the number of
shares of Common Stock then purchasable under this Warrant or, if only a portion of the Warrant is being exercised, the number
of shares of Common Stock as to which the Warrant is being exercised.

 

A = the Fair Market
Value (defined below) of one share of Common Stock on the Exercise Date.

 

B = the Exercise
Price (as adjusted pursuant to the provisions of this Warrant).

 

For purposes of this Section 2, in the case of a
Cashless Exercise, the “Exercise Date” shall mean the day on which the Holder delivers the Exercise Notice to the
Company by hand or e-mail, or the day the Holder deposits the Exercise Notice in a facility of the US mails or with a
recognized overnight courier, and “Fair Market Value” of one share of Common Stock on the Exercise Date shall
have one of the following meanings:

 

(1)if the Common
Stock is traded on the NYSE MKT or other national securities exchange registered with the Securities and Exchange Commission pursuant
to the Securities Exchange Act of 1934, as amended, the Fair Market Value shall be deemed to be the average of the Closing Prices
over a five trading day period ending on the Exercise Date. For the purposes of this Agreement, “Closing Price” means
the closing sale price of one share of Common Stock, as reported by NYSE MKT or such other such national securities exchange,
or if NYSE MKT or such other national securities exchange does not publish such information, Bloomberg L.P; or

 

(2)if the Common
Stock is not traded on a national securities exchange, the Fair Market Value shall be deemed to be the average of the closing
bid and asked prices over the ten (10) Trading Day period ending on the Exercise Date; or

 

(3)if neither
(1) nor (2) is applicable, the Fair Market Value shall be at the commercially reasonable price per share which the Company could
obtain on the Exercise Date from a willing buyer (not a current employee or director) for shares of Common Stock sold by the Company,
from authorized but unissued shares, as determined in good faith by the Company’s Board of Directors.

     

     

    

b) Surrender.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the
Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three Trading Days of the date the
final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of
the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any
objection to any Notice of Exercise Form within three Business Days of receipt of such notice. In the event of any dispute or
discrepancy, the records of the Company shall be controlling and determinative in the absence of manifest error. The Holder and
any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof.

 

c)Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $US0.03, subject to adjustment hereunder
(the “Exercise Price”).

 

d)Mechanics
of Exercise.

 

i.         Authorization
of Warrant Shares. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase
rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be
duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the
Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).

 

ii.         Delivery of Certificates Upon Exercise. Certificates for shares purchased
hereunder shall be transmitted by the transfer agent of the Company to the Holder by crediting the account of the Holder’s
prime broker with the Depository Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”) system
if the Company is a participant in such system, and otherwise by physical delivery to the address specified by the Holder in the
Notice of Exercise within 3 Trading Days from the delivery to the Company of the Notice of Exercise Form, surrender of this Warrant
(if required) and payment of the aggregate Exercise Price as set forth above (“Warrant Share Delivery Date”).
This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company. The Warrant Shares
shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have
become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company
of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section 2(c)(v) prior to the issuance
of such shares, have been paid.

 

iii.         Delivery of New Warrants Upon Exercise. If this Warrant shall have
been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time
of delivery of the certificate or certificates representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights
of Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.

 

iv.         No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company
shall at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.

     

     

    

v.         Charges,
Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses
shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may
be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be
issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the
Assignment Form attached hereto duly executed by the Holder; and the Company may require, as a condition thereto, the payment
of a sum sufficient to reimburse it for any transfer tax incidental thereto.

 

vi.         Closing of Books. The Company will not close its stockholder books
or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

 

Section 3.Certain Adjustments.

 

a)             
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (A) pays a stock dividend or
otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (B) subdivides outstanding shares of Common Stock into a larger number of shares, (C) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (D) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted.
Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date
in the case of a subdivision, combination or re-classification.

 

b)             Fundamental
Transaction. If, at any time while this Warrant is outstanding, (A) the Company effects any merger or consolidation of
the Company with or into another Person, (B) the Company effects any sale of all or substantially all of its assets in one or
a series of related transactions, (C) any tender offer or exchange offer (whether by the Company or another Person) is
completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities,
cash or property, or (D) the Company effects any reclassification of the Common Stock or any compulsory share exchange
pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (each
“Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the
right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, the number of shares of Common Stock of the successor or acquiring corporation or of the
Company, if it is the surviving corporation, and any additional consideration (the “Alternate
Consideration”) receivable as a result of such merger, consolidation or disposition of assets by a Holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such event. For purposes of any
such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such
Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a
reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of
Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the
Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the
foregoing provisions and evidencing the Holder’s right to exercise such warrant into Alternate Consideration. The terms
of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or
surviving entity to comply with the provisions of this Section 3(b) and insuring that this Warrant (or any such replacement
security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. 

     

     

    

Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction that is an all cash transaction, whereby the holders of
Common Stock immediately prior to such event are to receive cash in substitution for their shares, and, upon the exercise of
this Option the Holder is entitled to receive an amount in cash which, on a per share basis is less than the Exercise Price
then in effect, this Agreement shall be deemed to have terminated as of the date of such change.

 

c)             
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

d)            
Voluntary Adjustment By Company. The Company may at any time during the term of this Warrant reduce the then current Exercise
Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company.

 

e)             
Notice to Holder.

 

i.         Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting forth a brief
statement of the facts requiring such adjustment. If the Company enters into a Variable Rate Transaction (as defined in the
Purchase Agreement) despite the prohibition thereon in the Purchase Agreement, the Company shall be deemed to have issued
Common Stock or Common Stock Equivalents at the lowest possible conversion or exercise price at which such securities may be
converted or exercised.

 

ii.         Notice to Allow Exercise by Holder. If (A) the Company shall declare
a dividend (or any other distribution in whatever form) on the Common Stock; (B) the Company shall declare a special nonrecurring
cash dividend on or a redemption of the Common Stock; (C) the Company shall authorize the granting to all holders of the Common
Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights; (D) the approval
of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation
or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, of any
compulsory share exchange whereby the Common Stock is converted into other securities, cash or property; (E) the Company shall
authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company; then, in each case,
the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register of the Company,
at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date
on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record
is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale,
transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the
Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice
or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified
in such notice. The Holder is entitled to exercise this Warrant during the 20-day period commencing on the date of such notice
to the effective date of the event triggering such notice.

     

     

    

Section 4.Transfer of Warrant.

 

a)              Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the
provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation,
any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the
Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto
duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the
making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new
Warrant or Warrants in the name of the assignee or assignees and in the denomination or denominations specified in such
instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. A Warrant, if properly assigned, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.

 

b)            
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice.

 

c)             
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d)            
Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant,
the transfer of this Warrant shall not be registered pursuant to an effective registration statement under the Securities Act
and under applicable state securities or blue sky laws, the Company may require, as a condition of allowing such transfer, that
(i) the Holder or transferee of this Warrant, as the case may be, furnish to the Company a written opinion of counsel acceptable
to the Company (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions)
to the effect that such transfer may be made without registration under the Securities Act and under applicable state securities
or blue sky laws, and (ii) the Holder or transferee execute and deliver to the Company an investment letter in form and substance
acceptable to the Company, and (iii) the transferee is not a U.S. Person (as defined in Rule 902(k) of Regulation S under the
Securities Act or is an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) promulgated
under the Securities Act..

 

Section 5.Miscellaneous.

 

a)             
No Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights
as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(c)(ii).

 

b)             Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating
to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it
(which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such
Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like
tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

c)             
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.

     

     

    

d)            
Authorized Shares.

 

The Company
covenants that during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the
exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure
that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the Trading Market upon which the Common Stock may be listed.

 

Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise
of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under
this Warrant.

 

Before taking any action which would result in an
adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall
obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.

 

e)             
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the provisions of the Purchase Agreement.

 

f)             
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
will have restrictions upon resale imposed by state and federal securities laws.

 

g)            
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the
fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including
those of appellate proceedings, incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any
of its rights, powers or remedies hereunder.

 

h)            
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered in accordance with the notice provisions of the Purchase Agreement.

 

i)              
Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability
of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.

     

     

    

j)              
Remedies. Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and
not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)            
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be
enforceable by any such Holder or holder of Warrant Shares.

 

l)              
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.

 

m)           
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)            
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

 

	 	EVENT CARDIO
        GROUP, INC.

         

         

	 	By:__________________________________________

        John Bentivoglio

        President and CEO

    	 

    	 

    

NOTICE OF EXERCISE

(paid in cash)

 

To:
EVENT CARDIO GROUP, INC.

 

 

(1)  The undersigned
hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)  Payment
shall take the form of in lawful money of the United States.

 

(3)  Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is
specified below:

_______________________________

 

 

The Warrant Shares shall be delivered to the
following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4)  Status of Holder
Exercising Warrant: The undersigned is (check the applicable boxe(s) below):

 

[ ] an “accredited investor” as defined in Rule
501(a) of Regulation D promulgated under the Securities Act of 1933, as amended; or

 

[ ] not a “U.S. Person” as defined in of Rule
902(k) of Regulation S under the Securities Act.

 

 

Name: ____________________________________________________

 

Signature: _________________________________________________

 

Date: ______________________________________________________

    	 

    	 

    

NOTICE OF EXERCISE

(cashless exercise)

 

To:
EVENT CARDIO GROUP, INC.

 

 

(1)   The undersigned
hereby elects to convert his right to purchase _______ Warrant Shares of Common Stock of Event Cardio Group, Inc. (the “Company”),
as provided in the Warrant Agreement dated February , 2016 (the “Stock Option Agreement”), into ____ shares of the
Common Stock of the Company (based on a fair market value per share of $_______ ). Please issue the shares in accordance with
the instructions given below.

 

(2)  Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is
specified below:

_______________________________

 

 

The Warrant Shares shall be delivered to the
following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

(3)  Status of Holder
Exercising Warrant: The undersigned is (check the applicable boxe(s) below):

 

[ ] an “accredited investor” as defined in Rule
501(a) of Regulation D promulgated under the Securities Act of 1933, as amended; or

 

[ ] not a “U.S. Person” as defined in of Rule
902(k) of Regulation S under the Securities Act.

 

 

Name: ____________________________________________________

 

Signature: _________________________________________________

 

Date: ______________________________________________________

    	 

    	 

    

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute this form and
supply required information.

Do not use this form to exercise the warrant.)

 

 

 

FOR VALUE RECEIVED, [____] all of or [_______] shares of
the foregoing Warrant and all rights evidenced thereby are hereby assigned to _______________________________________________
whose address is _______________________________________________________________.

 

_______________________________________________________________

 

Dated: ______________,
_______

 

 

Holder’s Signature:_____________________________

 

Holder’s Address:_____________________________

 

_____________________________

 

 

 

Signature Guaranteed: ___________________________________________

 

 

NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity
should file proper evidence of authority to assign the foregoing Warrant.EXHIBIT 10.1

 

 

 

 

 

ASSET PURCHASE AGREEMENT

 

among:

 

Gulf Coast Billing, Inc.,

 

a Texas corporation,

 

Rhonda Roberts-Turner, 

 

an Individual,

 

and

 

Medical Transcription Billing,
Corp.,

 

a Delaware corporation

 

____________________________

 

Dated on February 15, 2016

 

____________________________

 

 

 

 

 

 

 

 

 

 

 

TABLE OF CONTENTS

 

 

	 	 	Page
	1.	Sale of Assets; Related Transactions.	1
	1.1	Purchase and Sale of the Purchased Assets.	1
	1.2	Purchase Price	2
	1.3	Certain Post-Closing Rights and Responsibilities; Adjustments.	2
	1.4	Payment of the Purchase Price.	2
	1.5	Reporting.	3
	1.6	Sales Taxes	3
	1.7	Closing	3
	 	 	 
	2.	Representations and Warranties of the Seller and Shareholders.	4
	2.1	Corporate Representations and Warranties.	4
	2.2	Financial Statements	5
	2.3	Absence Of Changes	6
	2.4	Title To Purchased Assets	7
	2.5	Receivables	7
	2.6	Clients	7
	2.7	Intellectual Property; Privacy	8
	2.8	Contracts	10
	2.9	Liabilities	11
	2.10	Compliance with Legal Requirements	11
	2.11	Governmental Authorizations	13
	2.12	Tax Matters	14
	2.13	Employee and Labor Matters	14
	2.14	Insurance	15

 

    	 	- i -	 

     

    

 

	2.15	Certain Payments, Etc.	16
	2.16	Proceedings; Orders	16
	2.17	Authority; Binding Nature of Agreements	17
	2.18	Non-Contravention; Consents	17
	2.19	Brokers	18
	2.20	Full Disclosure	18
	 	 	 
	3.	Representations and Warranties of the Purchaser.	18
	3.1	Representations and Warranties of the Purchaser.	18
	3.2	Authority; Binding Nature Of Agreements	20
	3.3	Non-Contravention	20
	 	 	 
	4.	Indemnification, Etc.	20
	4.1	Survival of Representations and Covenants	20
	4.2	Indemnification By the Seller and Shareholder.	20
	4.3	Indemnification By The Purchaser.	21
	4.4	Conditions of Indemnification	22
	 	 	 
	5.	Certain Post-Closing Covenants.	22
	5.1	Further Actions	22
	5.2	Confidentiality; Publicity	23
	5.3	Employees.	23
	5.4	Accounts Receivable	24
	5.5	Non-Solicitation	24
	5.6	Change of Name.	24
	 	 	 
	6.	Miscellaneous Provisions.	24
	6.1	Further Assurances	24
	6.2	Sole Representations and Warranties	24
	6.3	Fees and Expenses	25

 

    	 	- ii -	 

     

    

 

	6.4	Notices	25
	6.5	Headings	25
	6.6	Counterparts	25
	6.7	Unattached Exhibits	25
	6.8	Remedies Cumulative; Specific Performance.	26
	6.9	Waiver.	26
	6.10	Amendments	26
	6.11	Severability	26
	6.12	Entire Agreement	26
	6.13	Knowledge	27
	6.14	Construction	27
	6.15	Choice	27

 

 

 

 

 

 

 

    	 	- iii -	 

     

    

 

ASSET
PURCHASE AGREEMENT

 

This
Asset Purchase Agreement is entered into on February 15, 2016, by and among: Gulf
Coast Billing, Inc., a Texas corporation (the “Seller”), Rhonda Roberts-Turner
(the “Shareholder”) and Medical Transcription Billing, Corp.,
a Delaware corporation (the “Purchaser”). Certain capitalized terms used in this Agreement are defined in Exhibit “A”.

 

Recitals

 

Whereas,
the Purchaser desires to purchase the assets of the Seller, which is engaged in the business of providing Medical Billing Services
(“Business”).

 

Whereas,
Seller wishes to provide for the sale of substantially all of the assets of the Seller to the Purchaser on the terms set forth
in this Agreement.

 

Now Therefore,
in consideration of the respective covenants, agreements, representations, warranties and indemnities herein contained and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby covenant and
agree as follows:

 

Agreement

 

The parties to this Agreement, intending to
be legally bound, agree as follows:

 

		1.	Sale of Assets; Related Transactions.

 

1.1 
Purchase and Sale of the Purchased Assets. As of the Closing Date, and
on the terms and subject to the fulfillment of the conditions of this Agreement, the Seller agrees to sell, assign and transfer
all rights, title and interest in and to certain tangible and intangible assets of the Seller to the Purchaser, and the Purchaser
agrees to purchase from the Seller the Purchased Assets, free and clear of all Encumbrances. The Purchased Assets consist of:
(a) all of the Seller’s rights and remedies, as of and from the Closing Date, concerning each Medical Billing Agreement;
(b) all goodwill of Seller related to the Medical Billing Agreements and other Purchased Assets; (c) all software programs and/or
applications owned by Seller (including any associated licenses which are assignable); (d) any other assets that are owned by
Seller that are needed for the conduct of the business of the Seller, provided that the Purchased Assets shall not include any
Excluded Assets; and (e) all Intellectual Property of Seller, including such right, title and interest in and to the name
“Gulf Coast Billing Services” as Seller possess.

 

(b)              
Excluded Assets. The Purchased Assets shall not include any property listed on Exhibit “B”.

 

1.2 
Purchase Price.

 

The aggregate consideration payable by the Purchaser
to the Seller for the Purchased Assets (the “Purchase Price”) will, subject to adjustment in accordance with Section
1.3, be:

 

    	 	A-1	 

     

    

(a)               
Initial Payment on the Closing Date. The first payment amount will be One Million, Two Hundred and Fifty Thousand
Dollars ($1,250,000) (“Initial Payment”); plus

 

(b)              
Installment Payments. Twelve consecutive quarterly payments (“Installment Payments”) equal to twenty-eight
percent (28%) of all fees, if any, that are earned between March 1, 2016 and February 28, 2019 by Purchaser from Clients and received
during the respective quarter, less 1/12th of the Initial Payment.

 

(c)               
February Revenue. Contemporaneous with the first Installment Payment, Purchaser shall also pay Seller an amount equal
to 50% of all fees earned and received by Seller relative to Medical Billing Services performed during February 2016.

 

 

 

1.3 
Certain Post-Closing Rights and Responsibilities; Adjustments.

 

(a)               
Except as otherwise set forth herein:

 

(i)                
Seller will be solely responsible for all expenses that accrue relative to the Business and Purchased Assets though 11:59
P.M. Eastern Time on February 29, 2016;

 

(ii)              
Subject to Section 1.2 above, from and after the Closing Date, Purchaser will receive all revenues relating to the Business,
Purchased Assets and Assumed Liabilities and shall be responsible for issuing monthly invoices at the end of February 2016 and
thereafter; and

 

(b)              
Any Adjustments may be adjusted directly between the Parties at the time of the payment of the Installment Payments or such
other time as mutually agreed upon by the Parties.

 

1.4 
Payment of the Purchase Price. Purchaser shall pay the Purchase Price to Seller as follows:

 

(a)               
The Initial Payment shall be paid by Purchaser to Seller on the Closing Date;

 

(b)              
The first of twelve consecutive quarterly Installment Payments shall be paid by Purchaser to Seller on or before July 20,
2016 for relevant payments received by Purchaser from the Clients on or before June 30, 2016, with subsequent payments to be received
within 20 days of the end of each respective quarter (the first Installment Payment shall cover the period of February 15, 2016
through June 30, 2016; thereafter installment payments will be made on a calendar quarterly basis).

 

1.5 
Reporting. Seller and its agents shall have the right to review, copy and audit the Purchaser’s relevant
financial records from time to time to the extent reasonably required to enable Purchaser to determine if the Installment Payments
and the and February Revenue payment were computed correctly. Each party shall bear its own costs and expenses as it relates to
any such review or audit.

 

    	 	A-2	 

     

    

1.6  Sales
Taxes. The Seller shall bear and pay, and shall reimburse the Purchaser and the Purchaser’s affiliates for, any sales taxes,
transfer taxes, documentary charges, recording fees or similar taxes that may become payable in connection with the sale of the
Purchased Assets to the Purchaser.

 

1.7  Closing.

 

(a)               
The closing of the sale of the Purchased Assets to the Purchaser (the “Closing”) shall take place at the offices
of Purchaser in Somerset, New Jersey as of Noon, Eastern Time, on February 15, 2016, or at such other place and/or date as the
Purchaser and Seller may agree upon.

 

(b)              
At the Closing:

 

(i)                
The Seller shall execute and deliver to the Purchaser such bills of sale (in the form attached as Exhibit “C”),
endorsements, and other documents as may (in the reasonable judgment of the Purchaser or its counsel) be necessary or appropriate
to convey, transfer and deliver to the Purchaser good and valid title to the Purchased Assets free of any Encumbrances;

 

(ii)              
The Purchaser shall pay the Initial Payment amount;

 

(iii)            
The Purchaser shall execute and deliver to the Seller the Assumption Agreement (in the form attached as Exhibit “D”);

 

(iv)            
Seller shall deliver to Purchaser possession and custody of all medical and financial records in Seller’s possession
for the Seller’s current and former Clients, and Purchaser shall maintain such records in compliance with all applicable
laws and the Seller’s Medical Billing Agreements.

 

		2.	Representations and Warranties of th e Seller and Shareholders.

 

The Seller and Shareholder represent, jointly
and severally, and warrants to the Purchaser as follows:

 

2.1 
Corporate Representations and Warranties.

 

(a)               
Organization and Existence of the Seller. The Seller is a corporation organized and validly existing under the Laws
of Texas.

 

(b)              
Corporate Power and Capacity. The Seller has the corporate power, authority and capacity to own or lease its assets,
including the Purchased Assets, and to carry on the Business as now being conducted by it.

 

    	 	A-3	 

     

    

(c)               
Validity of Agreement.

 

(i)                
The Seller has all necessary corporate power, authority and capacity to enter into and perform its obligations under this
Agreement and any other agreements or instruments to be delivered or given by it pursuant to this Agreement.

 

(ii)              
The execution, delivery and performance by the Seller and Shareholder of this Agreement and the consummation of the Transactions
have been duly authorized by all necessary corporate action on the part of the Seller.

 

(iii)            
This Agreement and any other agreements entered into pursuant to this Agreement to which the Seller and Shareholder is a
party constitute or will constitute legal, valid and binding obligations of the Seller and Shareholder enforceable against the
Seller and Shareholder in accordance with their respective terms, except as enforcement may be limited by bankruptcy, insolvency
or other Laws affecting the rights of creditors generally and except that equitable remedies may be granted only in the discretion
of a court of competent jurisdiction.

 

(d)              
Authorizations. There is no requirement for the Seller or Shareholder to make any filing with, give any notice to
or obtain any consent or Authorization from any Governmental Agency as a condition to the lawful consummation of the Transactions.

 

(e)               
No Violation. The execution and delivery of this Agreement by the Seller and the Shareholder the consummation of
the Transactions and the fulfillment by the Seller and Shareholder of the terms, conditions and provisions hereof will not (with
or without the giving of notice or lapse of time, or both):

 

(i)                
contravene or violate or result in a breach or a default under or give rise to a right of termination, amendment or cancellation
or the acceleration of any obligations of the Seller under:

 

A.               
any Law;

 

B.                
any judgment, order, writ, injunction or decree of any Governmental Agency having jurisdiction over the Seller;

 

C.                
the constating documents or any resolutions of the Seller; or

 

(ii)              
result in the creation or imposition of any Encumbrance on any of the Purchased Assets.

 

(f)               
No Other Agreements to Purchase. Except for the Purchaser’s rights pursuant to this Agreement, no Person has
any option, warrant, right, call, commitment, conversion right, right of exchange or other Contract or any right or privilege (whether
by Law, pre-emptive or contractual) capable of becoming an option, commitment, conversion right, right of exchange or other Contract
for the purchase from the Seller of any of the Purchased Assets.

 

    	 	A-4	 

     

    

2.2  Financial
Statements. The Seller and Shareholder delivered to the Purchaser the following financial statements (collectively, the “Financial
Statements”): (a) the unaudited balance sheets of the Seller as of December 31, 2014 and 2015 by quarter and as of the Closing
Date, the related statements of income and retained earnings for 2014 by quarter and 2015 by quarter and as of the Closing Date,
and the statements of cash flows for the years 2014 and 2015 and as of the Closing Date. The Financial Statements are accurate
and complete in all material respects, have been prepared in accordance with generally accepted accounting principles (“GAAP”)
applied on a consistent basis throughout the periods covered (except that the interim financial statements referred to in clause
“(a)”of this Section 2.2 do not have notes) and present fairly in all material respects the financial position of the
Seller as of the respective dates thereof and the results of operations and cash flows of the Seller for the periods covered thereby.

 

Seller shall deliver completed Financial Statements
for the years 2014, 2015 and through the Closing Date by April 1, 2016. Seller shall be responsible for paying any necessary fees
to Seller’s accounting firm for the preparation of such Financial Statements.

 

Purchaser will have the option, at its sole expense,
to audit or review such statements internally or retain a public accounting firm to audit or review such statements for the purpose
of complying with SEC requirements and Seller will provide full cooperation and access to work papers and support materials as
requested for such audit or review. Depending on the Sellers’ Financial Statements, Purchaser may be required to file audited
financial statements with the SEC within 74 days of closing.

 

Seller shall also provide Purchaser with the following
on or before Closing: contracts with all current customers and suppliers, copies of invoices for each customer for the last 6 months,
along with copies of all reports sent to customers on a regular basis, any special invoicing instructions, vendor invoices and
contracts, leases, personnel records for all employees being hired, and all documentation for software and systems used in the
business. Subject to the mutual consent of the Parties, some of the aforementioned documents maybe provided at a later date.

 

2.3  Absence
Of Changes. Except as set forth in Part 2.3 of the Disclosure Schedule since the date of the Financial Statements:

 

(a)               
there has not been any adverse change in, and no event has occurred that might have an adverse effect on, the business,
condition, assets, liabilities, operations, financial performance, net income or prospects of the Seller;

 

(b)              
there has not been any loss, damage or destruction to, or any interruption in the use of, any of the assets of the Seller
(whether or not covered by insurance);

 

(c)               
the Seller and Shareholder has not purchased or otherwise acquired any asset from any other Person, except for supplies
acquired by the Seller in the Ordinary Course of Business;

 

(d)              
the Seller has not leased or licensed any asset from any other Person;

 

    	 	A-5	 

     

    

(e)               
the Seller has not made any capital expenditure;

 

(f)               
the Seller has not sold or otherwise transferred, or leased or licensed, any asset to any other Person;

 

(g)              
the Seller has not written off as uncollectible, or established any extraordinary reserve with respect to, any account receivable
or other indebtedness;

 

(h)              
the Seller has not made any loan or advance to any other Person;

 

(i)                
the Seller and Shareholder has not (i) established or adopted any Seller Employee Plan, or (ii) paid any bonus
or made any profit-sharing or similar payment to, or increased the amount of the wages, salary, commissions, fees, fringe benefits
or other compensation or remuneration payable to, any of its directors, officers, employees or independent contractors;

 

(j)                
no Contract by which the Seller and Shareholder or any of the assets owned or used by the Seller and Shareholder is or was
bound, or under which the Seller and Shareholder has or had any rights or interest, including any Medical Billing Agreement, have
been amended or terminated and the Seller and Shareholder has no knowledge of any pending amendments or terminations contemplated
by Seller’s Clients;

 

(k)              
the Seller and Shareholder has not incurred, assumed or otherwise become subject to any Liability, other than accounts payable
(of the type required to be reflected as current liabilities in the “liabilities” column of a balance sheet prepared
in accordance with GAAP) incurred by the Seller in bona fide transactions entered into in the Ordinary Course of Business;

 

(l)                
the Seller and Shareholder has not discharged any Encumbrance or discharged or paid any indebtedness or other Liability,
except for accounts payable that (i) are reflected as current liabilities in the “liabilities” column of the Unaudited
Interim Balance Sheet or have been incurred by the Seller since the date of the Unaudited Interim Balance Sheet, in bona fide transactions
entered into in the Ordinary Course of Business, and (ii) have been discharged or paid in the Ordinary Course of Business;

 

(m)            
the Seller and Shareholder has not forgiven any debt or otherwise released or waived any right or claim;

 

(n)              
the Seller and Shareholder has not changed any of its methods of accounting or accounting practices in any respect;

 

(o)              
the Seller and Shareholder has not entered into any transaction or taken any other action outside the Ordinary Course of
Business; and

 

(p)              
the Seller and Shareholder has not agreed, committed or offered (in writing or otherwise) to take any of the actions referred
to in clauses “(c)”through “(o)”above.

 

    	 	A-6	 

     

    

2.4  Title
To Purchased Assets. The Seller and Shareholder owns, and has good and valid title to, all of the Purchased Assets purported
to be owned by it, including: all Purchased Assets identified in Section 1.1 of this Agreement; all Purchased Assets reflected
on the Unaudited Interim Balance Sheet; all Purchased Assets acquired by the Seller and Shareholder since the date of the Unaudited
Interim Balance Sheet; all rights of the Seller and Shareholder under Seller Contracts; and all other Purchased Assets reflected
in the books and records of the Seller and Shareholder as being owned by the Seller and Shareholders. All of said Purchased Assets
are owned by the Seller and Shareholder free and clear of any Encumbrances. Part 2.4 of the Disclosure Schedule identifies all
of the Purchased Assets that are being leased or licensed to the Seller and Shareholders. The Purchased Assets will collectively
constitute, as of the Closing Date, all of the properties, rights, interests and other tangible and intangible assets necessary
to enable the Seller and Shareholder to conduct the Business in the manner in which such business is currently being conducted.

 

2.5  Receivables.
Part 2.5 of the Disclosure Schedule provides an accurate and complete breakdown and aging of all accounts receivable, notes receivable
and other receivables of the Seller as of February 12, 2016, all of which are Excluded Assets. Seller shall provide an updated
Disclosure within fifteen (15) days post-closing.

 

2.6  Clients.
Part 2.6 of the Disclosure Schedule accurately identifies, and provides an accurate and complete breakdown of the revenues received
during the period January 1, 2015 through the Closing Date from each Client. Except as set forth in Part 2.6 of the Disclosure
Schedule, Seller and Shareholder has not received any notice or other communication (in writing or otherwise), and the Seller and
Shareholder has not received any other information, indicating that any Client identified or required to be identified in Part
2.6 of the Disclosure Schedule may cease doing business with the Seller and Shareholder or may otherwise reduce the volume of business
transacted by such Person with the Seller and Shareholder below historical levels.

 

2.7  Intellectual
Property; Privacy.

 

(a)               
Products and Services. Part 2.7(a) of the Disclosure Schedule accurately identifies and describes each Seller and
Shareholder Product currently being designed, developed, marketed, distributed, provided, licensed, or sold by the Seller and Shareholders.

 

(b)              
Registered IP. Part 2.7(b) of the Disclosure Schedule accurately identifies: (a) each item of Registered IP in which
the Seller and Shareholder has or purports to have an ownership interest of any nature (whether exclusively, jointly with another
Person, or otherwise); (b) the jurisdiction in which such item of Registered IP has been registered or filed and the applicable
registration or serial number; (c) any other Person that has an ownership interest in such item of Registered IP and the nature
of such ownership interest; and (d) each Seller Product identified in Part 2.7(b) of the Disclosure Schedule that embodies, utilizes,
or is based upon or derived from (or, with respect to Seller Products currently under development, that is expected to embody,
utilize, or be based upon or derived from) such item of Registered IP. The Seller has provided to the Purchaser complete and accurate
copies of all applications, correspondence with any Governmental Body, and other material documents related to each such item of
Registered IP.

 

    	 	A-7	 

     

    

(c)               
Inbound Licenses. Part 2.7(c) of the Disclosure Schedule accurately identifies: (a) each Contract pursuant to which
any Intellectual Property Right or Intellectual Property is or has been licensed, sold, assigned, or otherwise conveyed or provided
to the Seller (other than (i) agreements between the Seller and its employees in the Seller’s standard form thereof and (ii)
non-exclusive licenses to third-party software that is not incorporated into, or used in the development, testing, distribution,
maintenance, or support of, any Seller Product and that is not otherwise material to the Seller’s business); and (b) whether
the licenses or rights granted to Seller in each such Contract are exclusive or non-exclusive.

 

(d)              
Outbound Licenses. Part 2.7(d) of the Disclosure Schedule accurately identifies each Contract pursuant to which any
Person has been granted any license under, or otherwise has received or acquired any right (whether or not currently exercisable)
or interest in, any Seller IP. The Seller is not bound by, and no Seller IP is subject to, any Contract containing any covenant
or other provision that in any way limits or restricts the ability of the Seller to use, exploit, assert, or enforce any Seller
IP anywhere in the world.

 

(e)               
Royalty Obligations. Part 2.7(e) of the Disclosure Schedule contains a complete and accurate list and summary of
all royalties, fees, commissions, and other amounts payable by the Seller to any Person (other than sales commissions paid to employees
according to the Seller’s standard commissions plan) upon or for the sale, or distribution of any Seller Product or the use
of any Seller IP.

 

(f)               
Ownership Free and Clear. The Seller exclusively owns all right, title, and interest to and in the Seller IP free
and clear of any Encumbrances (other than licenses and rights granted pursuant to the Contracts identified in Part 2.7(f) of the
Disclosure Schedule).

 

(g)              
Protection of Proprietary Information. The Seller has taken all reasonable steps to maintain the confidentiality
of and otherwise protect and enforce their rights in all proprietary information pertaining to the Seller or any Seller Product.
Without limiting the generality of the foregoing, no portion of the source code for any software ever owned or developed by the
Seller has been disclosed or licensed to any escrow agent or other Person.

 

(h)              
Sufficiency. The Seller owns or otherwise has, and after the Closing the Purchaser will have, all Intellectual Property
Rights needed to conduct its business as currently conducted and planned to be conducted.

 

(i)                
Harmful Code. The Seller Products do not contain any “viruses,” “worms,” “time-bombs,”
“key-locks,” or any other devices that could disrupt or interfere with the operation of the Seller Products or equipment
upon which the Seller Products operate.

 

(j)                
Valid and Enforceable; No Infringement. All Seller IP is valid, subsisting, and enforceable. To the best
of the Seller’s Knowledge, no Person has infringed, misappropriated, or otherwise violated, and no Person is currently infringing,
misappropriating, or otherwise violating, any Seller IP. Part 2.7(j) of the Disclosure Schedule accurately identifies (and the
Seller has provided to the Purchaser a complete and accurate copy of) each letter or other written or electronic communication
or correspondence that has been sent or otherwise delivered by or to the Seller or any representative of the Seller regarding any
actual, alleged, or suspected infringement or misappropriation of any Seller IP, and provides a brief description of the current
status of the matter referred to in such letter, communication, or correspondence.

 

    	 	A-8	 

     

    

(k)              
No Infringement of Third Party IP Rights. The Seller has never infringed (directly, contributorily, by inducement,
or otherwise), misappropriated, or otherwise violated or made unlawful use of any Intellectual Property Right of any other Person
or engaged in unfair competition. No Seller Product, and no method or process used or incorporated in any Seller Product, infringes,
violates, or makes unlawful use of any Intellectual Property Right of, or contains any Intellectual Property misappropriated from,
any other Person. There is no legitimate basis for a claim that the Seller or any Seller Product has infringed or misappropriated
any Intellectual Property Right of another Person or engaged in unfair competition or that any Seller Product, or any method or
process used or incorporated in any Seller Product, infringes, violates, or makes unlawful use of any Intellectual Property Right
of, or contains any Intellectual Property misappropriated from, any other Person, and no such claim is pending or, to the best
of the Seller’s Knowledge, threatened against the Seller. The Seller has never received any notice or other communication
(in writing or otherwise) relating to any actual, alleged, or suspected infringement, misappropriation, or violation by the Seller,
any of their employees or agents, or any Seller Product of any Intellectual Property Rights of another Person, including any letter
or other communication suggesting or offering that the Seller obtain a license to any Intellectual Property Right of another Person.

 

2.8  Contracts.

 

(a)               
Part 2.8(a) of the Disclosure Schedule identifies each Medical Billing Agreement and each other Seller Contract. The Seller
has delivered to the Purchaser accurate and complete copies of all written Seller Contracts identified in Part 2.8(a) of the Disclosure
Schedule, including all amendments thereto. Each Seller Contract is valid and in full force and effect.

 

(b)              
Except as set forth in Part 2.8(b) of the Disclosure Schedule: (i) no Person has violated or breached, or declared or committed
any default under, any Seller Contract; (ii) no event has occurred, and no circumstance or condition exists, that might (with or
without notice or lapse of time) (A) result in a violation or breach of any of the provisions of any Seller Contract, (B) give
any Person the right to declare a default or exercise any remedy under any Seller Contract, (C) give any Person the right
to accelerate the maturity or performance of any Seller Contract, or (D) give any Person the right to cancel, terminate or modify
any Seller Contract; (iii) the Seller has not received any notice or other communication (in writing or otherwise) regarding any
actual, alleged, possible or potential termination, violation or breach of, or default under, or intention to reduce or limit the
scope of services or reduce the volume of the business under any Seller Contract; and (iv) the Seller has not waived any right
under any Seller Contract.

 

(c)               
To the best of the knowledge of the Seller and Shareholder each Person against which the Seller has any rights under any
Seller Contract is solvent and is able to satisfy all of such Person’s current monetary obligations and other obligations
and Liabilities thereunder.

 

    	 	A-9	 

     

    

(d)              
Except as set forth in Part 2.8(d) of the Disclosure Schedule, the Seller has never guaranteed or otherwise agreed to cause,
insure or become liable for, and the Seller has never pledged any of its assets to secure, the performance or payment of any obligation
or other Liability of any other Person.

 

(e)               
The performance of the Seller Contracts will not result in any violation of or failure to comply with any Legal Requirement.

 

(f)               
No Person is renegotiating, or has the right to renegotiate, any amount paid or payable to the Seller under any Seller Contract
or any other term or provision of any Seller Contract.

 

(g)              
The Seller has no knowledge of any basis upon which any party to any Seller Contract may object to (i) the assignment
to the Purchaser of any right under such Seller Contract, or (ii) the delegation to or performance by the Purchaser of any
obligation under such Seller Contract.

 

(h)              
The Assumed Contracts included in Part 2.8(h) of the Disclosure Schedule collectively constitute all of the Contracts necessary
to enable the Seller to conduct its business in the manner in which such business is currently being conducted.

 

(i)                
The Seller and Shareholder have provided Purchaser with complete copies of all written Medical Billing Agreements, including
any and all addenda thereto, with the Closing Date Clients, which are freely assignable to Purchaser without the need to obtain
any approval or consents from Clients or other parties.

 

2.9  Liabilities.

 

(a)               
Except as set forth in Part 2.9(a) of the Disclosure Schedule, the Seller has no Liabilities, except for: (i) liabilities
identified as such in the “liabilities” columns of the Unaudited Interim Balance Sheet; (ii) accounts payable (of the
type required to be reflected as current liabilities in the “liabilities” column of a balance sheet prepared in accordance
with GAAP) incurred by the Seller in bona fide transactions entered into in the Ordinary Course of Business since the date of the
Unaudited Interim Balance Sheet; and (iii) obligations under the Contracts listed in Part 2.9(a) of the Disclosure Schedule, to
the extent that the existence of such obligations is ascertainable solely by reference to such Contracts.

 

(b)              
The Seller has not, at any time, (i) made a general assignment for the benefit of creditors, (ii) filed, or had
filed against it, any bankruptcy petition or similar filing, (iii) suffered the attachment or other judicial seizure of all
or a substantial portion of its assets, (iv) admitted in writing its inability to pay its debts as they become due, (v) been
convicted of, or pleaded guilty or no contest to, any felony, or (vi) taken or been the subject of any action that may have
an adverse effect on its ability to comply with or perform any of its covenants or obligations under any of the Transactional Agreements.

 

    	 	A-10	 

     

    

2.10           Compliance with Legal Requirements.

 

(a)               
Except as set forth in Part 2.10(a) of the Disclosure Schedule: (a) the Seller is in full compliance with each Legal Requirement
that is applicable to it or to the conduct of its business or the ownership or use of any of its assets; (b) the Seller has at
all times been in full compliance with each Legal Requirement that is or was applicable to it or to the conduct of its business
or the ownership or use of any of its assets; (c) no event has occurred, and no condition or circumstance exists, that might (with
or without notice or lapse of time) constitute or result directly or indirectly in a violation by the Seller of, or a failure on
the part of the Seller to comply with, any Legal Requirement; and (d) the Seller has not received, at any time, any notice or other
communication (in writing or otherwise) from any Governmental Body or any other Person regarding (i) any actual, alleged,
possible or potential violation of, or failure to comply with, any Legal Requirement, or (ii) any actual, alleged, possible or
potential obligation on the part of the Seller to undertake, or to bear all or any portion of the cost of, any cleanup or any remedial,
corrective or response action of any nature, (d) to the best knowledge of Seller, none of Seller’s Clients are currently
subject to or have received notice concerning an impending claim, audit or review by a governmental or commercial payor, and the
Seller and Shareholder has delivered to the Purchaser an accurate and complete copy of each report, study, survey or other document
to which or the Seller has possession that addresses or otherwise relates to the compliance of the Seller with, or the applicability
to the Seller of, any Legal Requirement.

 

(b)              
None of the Seller, any officer, director, manager, member or Shareholder or, to the Seller’s Knowledge, any agent,
employee or independent contractor of the Seller has submitted any claims for reimbursement that are in violation of, nor has engaged
in any activity that is in violation of, the federal Medicare or federal or state Medicaid statutes, the federal TRICARE statute
(10 U.S.C. § 1071 et seq.), the civil False Claims Act of 1863 (31 U.S.C. § 3729 et seq.), criminal
false claims statutes (e.g., 18 U.S.C. §§ 287 and 1001), the Federal Health Care Program Anti-Kickback Statute
(42 U.S.C. § 1320a-7b(b)), the Program Fraud Civil Remedies Act of 1986 (31 U.S.C. § 3801 et seq.), Section 14
of Public Law 100-93, the anti-fraud and related provisions of HIPAA, or related regulations or other related or similar federal
or state laws and regulations (collectively, “Health Care Program Laws”), including, without limitation, the following:

 

(i)                
making or causing to be made a false statement or representation in any application for any benefit or payment;

 

(ii)              
making or causing to be made a false statement or representation for use in determining rights to any benefit or payment;

 

(iii)            
soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly,
in cash or kind (A) in return for referring an individual to a Person for the furnishing or arranging for the furnishing of any
item or service for which payment may be made in whole or in part under any Federal Health Care Program, or (B) in return for purchasing,
leasing or ordering, or arranging for or recommending purchasing, leasing or ordering of any good, facility, service or item for
which payment may be made in whole or in part under any Federal Health Care Program;

 

    	 	A-11	 

     

    

(iv)            
offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly,
in cash or in kind, to any person to induce such Person (A) to refer an individual to a person for the furnishing or arranging
of any item or service for which payment may be made in whole or in part p under a Federal Health Care Program, or (B) to purchase,
lease, order or arrange for or recommend purchasing, leasing or ordering of any good, facility, service or item for which payment
may be made in whole or in part under a Federal Health Care Program; or

 

(v)              
any other activity that violates any state or federal Legal Requirements, Permit requirements or Payor contractual obligations,
if any, relating to prohibiting fraudulent, abusive or unlawful practices connected in any way with the provision of health care
items or services or the billing for such items or services provided to a beneficiary of any Federal Health Care Program.

 

(c)               
The Seller is, and has at all times been, in all material respects in compliance with HIPAA and Subtitle D of the Health
Information Technology for Economic and Clinical Health Act (including all rules and regulations thereunder) (the “HITECH
Act”) and comparable state privacy and data security laws and regulations applicable to the Seller. The Seller has used and
disclosed, and uses and discloses, Protected Health Information (as defined in 45 C.F.R. § 160.103) (i) to the extent applicable,
in accordance with any limitations set forth in its customer or Payor agreements; and (ii) to perform functions, activities or
services in accordance with the limitations set forth in HIPAA, the HITECH Act, and applicable state privacy and data security
laws and regulations (to the extent not preempted by federal law). The Seller has not received, at any time, any written notice
from any Governmental Body or any other Person regarding any actual or suspected violation of, or failure to comply with, HIPAA,
the HITECH Act or applicable state privacy and data security laws and regulations. No breach has occurred with respect to any unsecured
Protected Health Information maintained by the Seller that is subject to the notification requirements of 45 C.F.R. part 164, Subpart
D, and no information security or privacy breach event has occurred that would require notification under any comparable state
laws applicable to the Seller. With regard to compliance with HIPAA, the HITECH Act, or applicable state privacy and data security
laws and regulations, the Seller has no obligation to undertake, or to bear all or any portion of the cost of, any mitigation,
notifications or any remedial, corrective or response action of any nature. The Seller Products comply with HIPAA, the HITECH Act
and applicable state privacy and data security laws and regulations.

 

2.11                     
Governmental Authorizations. Part 2.11 of the Disclosure Schedule identifies: (a) each Governmental Authorization
that is held by the Seller; and (b) each other Governmental Authorization that, to the best of the knowledge of the Seller and
Shareholder is held by any employee of the Seller and relates to or is useful in connection with the business of the Seller. The
Shareholder and the Seller has delivered to the Purchaser accurate and complete copies of all of the Governmental Authorizations
identified in Part 2.11 of the Disclosure Schedule, including all renewals thereof and all amendments thereto. Each Governmental
Authorization identified or required to be identified in Part 2.11 of the Disclosure Schedule is valid and in full force and effect.
Except as set forth in Part 2.11 of the Disclosure Schedule, to the best knowledge of Seller: (i) the Seller is and has at all
times been in full compliance with all of the terms and requirements of each Governmental Authorization identified or required
to be identified in Part 2.11 of the Disclosure Schedule; (ii) no event has occurred, and no condition or circumstance exists,
that might (with or without notice or lapse of time) (A) constitute or result directly or indirectly in a violation of or
a failure to comply with any term or requirement of any Governmental Authorization identified or required to be identified in Part
2.11 of the Disclosure Schedule, or (B) result directly or indirectly in the revocation, withdrawal, suspension, cancellation,
termination or modification of any Governmental Authorization identified or required to be identified in Part 2.11 of the Disclosure
Schedule; (iii) the Seller has never received any notice or other communication (in writing or otherwise) from any Governmental
Body or any other Person regarding (A) any actual, alleged, possible or potential violation of or failure to comply with any
term or requirement of any Governmental Authorization, or (B) any actual, proposed, possible or potential revocation, withdrawal,
suspension, cancellation, termination or modification of any Governmental Authorization; and (iv) all applications required to
have been filed for the renewal of the Governmental Authorizations required to be identified in Part 2.11 of the Disclosure Schedule
have been duly filed on a timely basis with the appropriate Governmental Bodies, and each other notice or filing required to have
been given or made with respect to such Governmental Authorizations has been duly given or made on a timely basis with the appropriate
Governmental Body. The Governmental Authorizations identified in Part 2.11 of the Disclosure Schedule constitute all of the Governmental
Authorizations necessary (i) to enable the Seller to conduct its business in the manner in which such business is currently
being conducted, and (ii) to permit the Seller to own and use its assets in the manner in which they are currently owned and
used.

 

    	 	A-12	 

     

    

2.12                     
Tax Matters.

 

(a)               
The Seller has filed all Tax Returns that it was required to file under applicable Legal Requirements. All such Tax Returns
were correct and complete in all respects and have been prepared in substantial compliance with all applicable Legal Requirements.
All Taxes due and owing by the Seller (whether or not shown on any Tax Return) have been paid. The Seller is not currently the
beneficiary of any extension of time within which to file any Tax Return. No claim has ever been made by an authority in a jurisdiction
where the Seller does not file Tax Returns that it is or may be subject to taxation by that jurisdiction. There are no Liens for
Taxes (other than Taxes not yet due and payable) upon any of the assets of the Seller.

 

(b)              
The Seller has withheld and paid all Taxes required to have been withheld and paid in connection with any amounts paid or
owing to any employee, independent contractor, creditor, stockholder, or other third party.

 

(c)               
No director or officer (or employee responsible for Tax matters) of the Seller expects any authority to assess any additional
Taxes for any period for which Tax Returns have been filed. No Proceedings are pending or being conducted with respect to the Seller.
The Seller has not received from any Governmental Body any (i) notice indicating an intent to open an audit or other review, (ii) request
for information related to Tax matters, or (iii) notice of deficiency or proposed adjustment of or any amount of Tax proposed,
asserted, or assessed by any Governmental Body against the Seller.

 

    	 	A-13	 

     

    

(d)              
The Seller has not waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect
to a Tax assessment or deficiency.

 

2.13                     
Employee and Labor Matters.

 

(a)               
Part 2.13(a) of the Disclosure Schedule accurately sets forth, with respect to each employee of the Seller (including any
employee of the Seller who is on a leave of absence or on layoff status):

 

(i)                
the name of such employee and the date as of which such employee was originally hired by the Seller;

 

(ii)              
such employee’s title, and a description of such employee’s duties and responsibilities;

 

(iii)            
the aggregate dollar amount of the compensation (including wages, salary, commissions, director’s fees, fringe benefits,
bonuses, profit-sharing payments and other payments or benefits of any type) received by such employee from the Seller with respect
to services performed in 2015;

 

(iv)            
such employee’s annualized compensation as of the date of this Agreement;

 

(v)              
each Seller Employee Plan in which such employee participates or is eligible to participate; and

 

(vi)            
any Governmental Authorization that is held by such employee and that relates to or is useful in connection with the Seller’s
business.

 

(b)              
The employment of each of the Seller’s employees is terminable by the Seller at will. The Seller has delivered to
the Purchaser accurate and complete copies of all employee manuals and handbooks, disclosure materials, policy statements and other
materials relating to the employment of the current and former employees of the Seller.

 

(c)               
Part 2.13(c) of the Disclosure Schedule accurately sets forth, with respect to each independent contractor of the Seller
(exclusive of attorneys, accountants, insurance agents and other professionals who have provided services to Seller):

 

(i)                
the name of such independent contractor and the date as of which such independent contractor was originally hired by the
Seller;

 

(ii)              
a description of such independent contractor duties and responsibilities;

 

(iii)            
the aggregate dollar amount of the compensation (including all payments or benefits of any type) received by such independent
contractor from the Seller with respect to services performed in 2015;

 

    	 	A-14	 

     

    

(iv)            
the terms of compensation of such independent contractor; and

 

(v)              
any Governmental Authorization that is held by such independent contractor and that relates to or is useful in connection
with the Seller’s business.

 

(d)              
Except as set forth in Part 2.13(d) of the Disclosure Schedule, the Seller is not a party to or bound by, and the Seller
has never been a party to or bound by, any employment agreement or any union contract, collective bargaining agreement or similar
Contract.

 

(e)               
None of the current or former independent contractors of the Seller could be reclassified as an employee. The Seller has
never had any temporary or leased employees. No independent contractor of the Seller is eligible to participate in any Seller Employee
Plan.

 

2.14                     
Insurance. Seller maintains insurance policies of a character and in such amounts as are customarily insured
against by similarly situated companies in the same or similar businesses. No insurer under any such insurance policy has canceled
or generally disclaimed Liability under any such policy and no notice of cancellation or termination has been received. Part 2.14
of the Disclosure Schedule accurately sets forth, with respect to each such insurance policy maintained by or at the expense of,
or for the direct or indirect benefit of, the Seller: (i) the name of the insurance carrier that issued such policy and the policy
number of such policy; (ii) whether such policy is a “claims made”or an “occurrences”policy; (iii) a description
of the coverage provided by such policy and the material terms and provisions of such policy (including all applicable coverage
limits, deductible amounts and co-insurance arrangements and any non-customary exclusions from coverage); (iv) the annual premium
payable with respect to such policy; and (v) a description of any claims pending, and any claims that have been asserted in the
past, with respect to such policy or any predecessor insurance policy.

 

2.15                     
Certain Payments, Etc. The Seller has not, and no officer, employee, agent or other Person associated with or
acting for or on behalf of the Seller has, at any time, directly or indirectly: (a) used any corporate funds (i) to make any
unlawful political contribution or gift or for any other unlawful purpose relating to any political activity, (ii) to make
any unlawful payment to any governmental official or employee, or (iii) to establish or maintain any unlawful or unrecorded
fund or account of any nature; (b) made any false or fictitious entry, or failed to make any entry that should have been made,
in any of the books of account or other records of the Seller; (c) made any payoff, influence payment, bribe, rebate, kickback
or unlawful payment to any Person; (d) performed any favor or given any gift which was not deductible for federal income tax purposes;
(e) made any payment (whether or not lawful) to any Person, or provided (whether lawfully or unlawfully) any favor or anything
of value (whether in the form of property or services, or in any other form) to any Person, for the purpose of obtaining or paying
for (i) favorable treatment in securing business, or (ii) any other special concession; or (f) agreed, committed or offered
(in writing or otherwise) to take any of the actions described in clauses “(a)”through “(e)”above.

 

2.16                     
Proceedings; Orders. Except as set forth in Part 2.16 of the Disclosure Schedule, there is no pending Proceeding,
and no Person has threatened in writing during the 12 months preceding the date of this Agreement to commence any Proceeding: (i)
that involves the Seller or that otherwise relates to or might affect the business of the Seller or any of the Purchased Assets
(whether or not the Seller is named as a party thereto); or (ii) that challenges, or that may have the effect of preventing, delaying,
making illegal or otherwise interfering with, any of the Transactions. Except as set forth in Part 2.16 of the Disclosure Schedule,
to the best knowledge of Seller, no event has occurred, and no claim, dispute or other condition or circumstance exists, that might
directly or indirectly give rise to or serve as a basis for the commencement of any such Proceeding. Except as set forth in Part
2.16 of the Disclosure Schedule, no Proceeding has been commenced by or against the Seller during the 12 months preceding the date
of this Agreement, and the Seller and Shareholder has delivered to the Purchaser accurate and complete copies of all pleadings,
correspondence and other written materials (to which the Seller has access) that relate to the Proceedings identified in Part 2.16
of the Disclosure Schedule. There is no Order to which the Seller and Shareholder or any of the assets owned or used by the Seller,
is subject. To the best of the knowledge of the Seller, no employee of the Seller is subject to any Order that may prohibit employee
from engaging in or continuing any conduct, activity or practice relating to the business of the Seller. There is no proposed Order
that, if issued or otherwise put into effect, (i) may have an adverse effect on the business, condition, assets, liabilities,
operations, financial performance, net income or prospects of the Seller or on the ability of Seller or Shareholder to comply with
or perform any covenant or obligation under any of the Transactional Agreements, or (ii) may have the effect of preventing,
delaying, making illegal or otherwise interfering with any of the Transactions.

 

    	 	A-15	 

     

    

2.17                     
Authority; Binding Nature of Agreements.

 

(a)               
The Seller has the absolute and unrestricted right, power and authority to enter into and to perform its obligations under
each of the Transactional Agreements to which it is or may become a party; and the execution, delivery and performance by the Seller
of the Transactional Agreements to which it is or may become a party have been duly authorized by all necessary action on the part
of the Seller and its members, manager and officers. This Agreement constitutes the legal, valid and binding obligation of the
Seller, enforceable against the Seller in accordance with its terms. Upon the execution of each of the other Transactional Agreements
at the Closing, each of such other Transactional Agreements to which the Seller is a party will constitute the legal, valid and
binding obligation of the Seller and will be enforceable against the Seller in accordance with its terms.

 

(b)              
The Shareholder has the absolute and unrestricted right, power and capacity to enter into and to perform his obligations
under each of the Transactional Agreements to which he is or may become a party. This Agreement constitutes the legal, valid and
binding obligation of the Shareholder enforceable against the Shareholder and Seller in accordance with its terms. Upon the execution
of each of the other Transactional Agreements at the Closing, each of such other Transactional Agreements to which the Shareholder
and Seller is a party will constitute the legal, valid and binding obligation the Shareholder and will be enforceable against the
Shareholder and Seller in accordance with its terms.

 

2.18                     
Non-Contravention; Consents. Except as set forth in Part 2.18 of the Disclosure Schedule, neither the execution
and delivery of any of the Transactional Agreements by Shareholder and the Seller, nor the consummation or performance by the Seller
and Shareholder of any of the Transactions, or the sale and assignment of the Purchased Assets to Purchaser, will directly or indirectly
(with or without notice or lapse of time):

 

    	 	A-16	 

     

    

(a)               
contravene, conflict with or result in a violation of, the certificate of formation, operating agreement or other organizational
documents of Seller;

 

(b)              
contravene, conflict with or result in a violation of, or give any Governmental Body or other Person the right to challenge
any of the Transactions or to exercise any remedy or obtain any relief under, any Legal Requirement or any Order to which the Seller,
or any of the assets of the Seller, is subject;

 

(c)               
cause any of the Purchased Assets to be reassessed or revalued by any taxing authority or other Governmental Body;

 

(d)              
contravene, conflict with or result in a violation of any of the terms or requirements of, or give any Governmental Body
the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is to be included in the
Purchased Assets or is held by the Seller or any employee of the Seller;

 

(e)               
contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any of Seller’s
Contracts;

 

(f)               
give any Person the right to (i) declare a default or exercise any remedy under any of Seller’s Contracts, (ii) accelerate
the maturity or performance of any Contract, or (iii) cancel, terminate or modify any such Contract; or

 

(g)              
result in the imposition or creation of any Encumbrance upon or with respect to any of the Purchased Assets.

 

Except as set forth in Part 2.18 of the Disclosure Schedule, the
Seller nor the Shareholder was not and will not be required to make any filing with or give any notice to, or to obtain any Consent
from, any Person in connection with the execution and delivery of any of the Transactional Agreements or the consummation or performance
of any of the Transactions.

 

2.19                     
Brokers. Purchaser has retained Corporate Finance Advisors, Inc. (Ron Salupo) as the “retained broker”and
shall be liable for brokerage fees due to same. Seller and Shareholder represents that it has not engaged any other broker in respect
of the Transactions. Seller and Purchaser shall each indemnify and hold the other harmless from and against any and all claims,
demands, causes of action, debts or liabilities arising out of or on account of a claim by any other broker, finder, investment
banker or agent that he, she or it is entitled to a commission or fees as a result of being retained or used by the other party.

 

2.20                     
Full Disclosure. None of the Transactional Agreements contains or will contain any untrue statement of any material
fact; and none of the Transactional Agreements omits or will omit to state any fact necessary to make any of the representations,
warranties or other statements or information contained therein not materially misleading. All of the information set forth in
the Disclosure Schedule, and all other information regarding the Seller and its business, condition, assets, liabilities, operations,
financial performance, net income and prospects that has been furnished to the Purchaser or any of the Purchaser’s Representatives
by or on behalf of Seller or Shareholder or by any Representative of the Seller or Shareholder is accurate and complete in all
material respects.

 

    	 	A-17	 

     

    

		3.	Representations and Warranties of the Purchaser.

 

The Purchaser represents and warrants, to and
for the benefit of the Seller, as follows:

 

3.1 
Representations and Warranties of the Purchaser.

 

The Purchaser represents and warrants to the
Seller and Shareholder as of the date of this Agreement as follows:

 

(a)               
Incorporation and Existence of the Purchaser. The Purchaser is a corporation duly formed and validly existing under
the Laws of State of Delaware.

 

(b)              
Validity of Agreement.

 

(i)                
The Purchaser has all necessary corporate power to enter into and perform its obligations under this Agreement and any other
agreements or instruments to be delivered or given by it pursuant to this Agreement.

 

(ii)              
The execution, delivery and performance by the Purchaser of this Agreement and the consummation of the Transactions have
been duly authorized by all necessary corporate action on the part of the Purchaser.

 

(iii)            
This Agreement and any other agreements entered into pursuant to this Agreement to which the Purchaser is a party constitute
or will constitute legal, valid and binding obligations of the Purchaser, enforceable against the Purchaser in accordance with
their respective terms, except as enforcement may be limited by bankruptcy, insolvency or other Laws affecting the rights of creditors
generally and except that equitable remedies may be granted only in the discretion of a court of competent jurisdiction.

 

(c)               
Authorizations. There is no requirement for the Purchaser to make any filing with, give any notice to or obtain any
consent or Authorization from any Governmental Agency or any other Third Party as a condition to the lawful consummation of the
Transactions.

 

(d)              
No Violation. The execution and delivery of this Agreement by the Purchaser, the consummation of the Transactions
and the fulfillment by the Purchaser of the terms, conditions and provisions hereof will not (with or without the giving of notice
or lapse of time, or both) contravene or violate or result in a breach or a default under or give rise to a right of termination,
amendment or cancellation or the acceleration of any obligations of the Purchaser under:

 

(i)                
any Law;

 

    	 	A-18	 

     

    

(ii)              
any judgment, order, writ, injunction or decree of any Governmental Agency having jurisdiction over the Purchaser;

 

(iii)            
the constating documents or any resolutions of the board of directors or Shareholder of the Purchaser; or

 

(iv)            
the provisions of any Contract to which the Purchaser is a party or by which it is, or any of its properties or assets are,
bound.

 

(e)               
No Knowledge of Inaccuracy of Seller’s Representations and Warranties. The Purchaser does not have any knowledge
that any of the representations or warranties of the Seller as set forth in this Agreement is in any way inaccurate or untrue.

 

3.2  Authority;
Binding Nature Of Agreements. The Purchaser has the absolute and unrestricted right, power and authority to enter into and
perform its obligations under this Agreement, and the execution and delivery of this Agreement by the Purchaser have been duly
authorized by all necessary action on the part of the Purchaser and its board of directors. The Purchaser has the absolute and
unrestricted right, power and authority to enter into and perform its obligations under the Transactional Agreements to which it
is or may become a party, and the execution, delivery and performance of the Transactional Agreements by the Purchaser have been
duly authorized by all necessary action on the part of the Purchaser and its board of directors. This Agreement constitutes the
legal, valid and binding obligation of the Purchaser, enforceable against it in accordance with its terms. Upon the execution and
delivery of the Transactional Agreements at the Closing, the Transactional Agreements will constitute the legal, valid and binding
obligations of the Purchaser, enforceable against the Purchaser in accordance with their terms.

 

3.3  Non-Contravention.
Neither the execution and delivery by Purchaser of any of the Transactional Agreements nor the consummation or performance by the
Purchaser of the Transactions will directly or indirectly (with or without notice or lapse of time): (i) contravene, conflict with
or result in a violation of, the certificate of incorporation or by-laws of Purchaser; (ii) contravene, conflict with or result
in a violation of, or give any Governmental Body or other Person the right to challenge any of the Transactions or to exercise
any remedy or obtain any relief under, any Legal Requirement or any Order to which the Purchaser is subject; or (iii) contravene,
conflict with or result in a violation or breach of, or result in a default under, any provision of any material Contract to which
the Purchaser is a party.

 

		4.	Indemnification, Etc.

 

4.1  Survival
of Representations and Covenants. Subject to the limitations and other provisions of this Agreement, the representations, warranties,
and covenants contained herein shall survive the Closing and shall remain in full force and effect through the applicable statute
of limitations from the Closing Date. All covenants and agreements of the parties contained herein shall survive the Closing indefinitely
or for the period explicitly specified therein. Notwithstanding the foregoing, any claims asserted in good faith with reasonable
specificity (to the extent known at such time) and in writing by notice from the non-breaching party to the breaching party prior
to the expiration date of the applicable survival period shall not thereafter be barred by the expiration of the relevant representation
or warranty and such claims shall survive until finally resolved.

 

    	 	A-19	 

     

    

4.2 
Indemnification By the Seller and Shareholder.

 

(a)               
The Seller and Shareholder jointly and severally, shall hold harmless and indemnify each of the Indemnitees from and against,
and shall compensate and reimburse each of the Indemnitees for, any Damages that are directly or indirectly suffered or incurred
by any of the Indemnitees or to which any of the Indemnitees may otherwise become subject at any time (regardless of whether or
not such Damages relate to any third-party claim) and that arise directly or indirectly from or as a direct or indirect result
of, or are directly or indirectly connected with:

 

(i)                
any Breach of any of the representations or warranties of Seller or Shareholder contained in this Agreement, the other Transactional
Agreements, or instrument delivered by or on behalf of Seller or Shareholder pursuant to this Agreement, as of the date such representation
or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations
and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference
to such specified date);

 

(ii)              
any Breach or non-fulfillment of any covenant, agreement or obligation to be performed by Seller or Shareholder pursuant
to this Agreement, the other Transactional Agreements or any certificate or instrument delivered by or on behalf of Seller or Shareholder
pursuant to this Agreement;

 

(iii)            
any Excluded Asset or any Liability of the Seller or Shareholder or of any Related Party, other than the Assumed Liabilities;
or

 

(iv)            
any claim or Proceeding against the Purchaser or any other Indemnitee by any Person based upon, resulting from or arising
out of the business, operations, properties, assets or obligations of Seller or Shareholder or any of its Affiliates conducted,
existing or arising on or prior to the Closing Date, other than the Assumed Liabilities.

 

(b)              
Subject to Section 4.2(c), Seller or Shareholder shall not be required to make any indemnification payment pursuant
to Sections 4.2(a)(i) or 4.2(a)(ii) for any Breach as set forth in such Sections until such time as the total amount of all Damages
(including the Damages arising from such Breach and all other Damages arising from any other Breaches of any representations or
warranties) that have been directly or indirectly suffered or incurred by any one or more of the Indemnitees, or to which any one
or more of the Indemnitees has or have otherwise become subject, exceeds $5,000. If the total amount of Damages exceeds $5,000,
the Indemnitees shall be entitled to be indemnified against and compensated and reimbursed for the entire amount of Damages.

 

    	 	A-20	 

     

    

4.3 
Indemnification By The Purchaser.

 

(a)               
The Purchaser shall hold harmless and indemnify the Seller and Shareholder from and against, and shall compensate and reimburse
the Seller for, any Damages that are directly suffered or incurred by the Seller or Shareholder or to which the Seller or Shareholder
may otherwise become subject at any time (regardless of whether or not such Damages relate to any third-party claim) and that arise
directly or indirectly from or as a direct or indirect result of, or are directly or indirectly connected with:

 

(i)                
any Breach of any of the representations or warranties of the Purchaser contained in this Agreement, the other Transactional
Agreements or in any certificate or instrument delivered by or on behalf of the Purchaser pursuant to this Agreement, as of the
date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except
for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined
with reference to such specified date);

 

(ii)              
any Breach or non-fulfillment of any covenant, agreement or obligation to be performed by the Purchaser pursuant to this
Agreement, the other Transactional Agreements or any certificate or instrument delivered by or on behalf of the Purchaser pursuant
to this Agreement;

 

(iii)            
any claim or Proceeding against the Seller of Shareholder by any Person based upon, resulting from or arising out of the
business, operations, properties, assets or obligations of Purchaser or any of its Affiliates conducted, existing or arising after
the Closing Date;

 

(iv)            
Purchaser’s use of Seller’s Medicare or Medicaid Provider or submitter numbers after the Closing Date to submit
claims for services provided by Seller after the Closing Date; or

 

(v)              
any failure on the part of the Purchaser to perform and discharge the assumed liabilities on a timely basis.

 

(b)              
Subject to Section 4.3(c), the Purchaser shall not be required to make any indemnification payment pursuant to Section
4.3(a) for any Breach of any of its representations and warranties until such time as the total amount of all Damages (including
the Damages arising from such Breach and all other Damages arising from any other Breaches of its representations or warranties)
that have been directly or indirectly suffered or incurred by the Seller, or to which the Seller has otherwise become subject,
exceeds $5,000 in the aggregate. If the total amount of such Damages exceeds $5,000 in the aggregate, the Seller shall be entitled
to be indemnified against and compensated and reimbursed for the entire amount of such Damages, and not merely the portion of such
Damages.

 

4.4 
Conditions of Indemnification. The obligations and liabilities of the Purchaser and Seller under Section 4.2
and 4.3, respectively, shall be subject to the terms and conditions set forth on Exhibit “H”. (see change
to Exhibit H)

 

    	 	A-21	 

     

    

		5.	Certain Post-Closing Covenants.

 

5.1  Further
Actions. From and after the Closing Date, the Seller shall cooperate with the Purchaser and the Purchaser’s affiliates
and Representatives, and shall execute and deliver such documents and take such other actions as the Purchaser may reasonably request,
for the purpose of evidencing the Transactions and putting the Purchaser in possession and control of all of the Purchased Assets.
Without limiting the generality of the foregoing, from and after the Closing Date, the Purchaser shall promptly remit to the Seller
any funds that are received by the Purchaser that clearly represents payment of receivables for services provided by Seller prior
to the Closing Date. The Seller: hereby irrevocably nominates, constitutes and appoints the Purchaser as the true and lawful attorney-in-fact
of the Seller (with full power of substitution) effective as of the Closing Date, and hereby authorizes the Purchaser, in the name
of and on behalf of the Seller, to execute, deliver, acknowledge, certify, file and record any document, to institute and prosecute
any Proceeding and to take any other action (on or at any time after the Closing Date) that the Purchaser may deem appropriate
for the purpose of (i) collecting, asserting, enforcing or perfecting any claim, right or interest of any kind that is included
in or relates to any of the Purchased Assets, (ii) defending or compromising any claim or Proceeding relating to any of the
Purchased Assets, or (iii) otherwise carrying out or facilitating any of the Transactions. The power of attorney referred
to in the preceding sentence is and shall be coupled with an interest and shall be irrevocable, and shall survive the dissolution
or insolvency of the Seller. Except as set forth above, in the event that fees or any other charges are remitted by a Client to
Seller or Shareholder for Medical Billing Services, all such payments shall promptly be remitted to the Purchaser. Seller shall
maintain sufficient funds and pay any necessary fees in the event of recoupment of receivables related to activities prior to the
Closing Date. In the event Seller fails to pay the recoupment Purchaser’s remedies shall not be limited by Sections 4.2,
6.15, and Exhibit H.

 

5.2  Confidentiality;
Publicity.

 

(a)               
Seller and Shareholder recognizes and acknowledges that it had in the past, currently has, and in the future may have, access
to certain confidential information of the Seller and the Purchaser regarding the Business and process that are valuable, special
and unique assets of Seller and the Purchaser. Seller and Shareholder agrees that it will not disclose such confidential information
to any person for any purpose or reason whatsoever, unless (i) such information becomes known to the public generally through no
fault of the Seller or (ii) disclosure is required by law or the order of any Government Body under color of law; provided, that
prior to disclosing any information pursuant to this clause (ii); provided that Seller shall give prior written notice thereof
to the Purchaser and provide the Purchaser with the opportunity to contest such disclosure. Because
of the difficulty of measuring economic losses as a result of the breach of the covenants in this Section 5.2, and because
of the immediate and irreparable damage that would be caused for which no other adequate remedy exists, Seller and Shareholder
agrees that, in the event of a breach by it of the foregoing covenants, the covenant may
be enforced against the Purchaser by injunction and restraining order, without the necessity of posting a bond.

 

    	 	A-22	 

     

    

(b)              
Seller shall ensure that, on and at all times after the Closing Date no press release or other publicity concerning any
of the Transactions is issued or otherwise disseminated by or on behalf of Seller without the Purchaser’s prior written consent.

 

5.3 
Employees. Seller agrees to permit Purchaser to utilize the Retained Employees to conduct the business acquired
by it pursuant to this Agreement through a date to be mutually agreed upon by the Parties during the post-closing transition period.
The Retained Employees shall report to a Purchaser employee or representative. In consideration of Purchaser’s utilization
of the Retained Employees, Purchaser agrees to reimburse Seller for the Transitional Costs that accrue during the period of utilization
of the respective Retained Employees. Purchaser shall have the right to direct Seller to terminate the employment of any or all
of the Retained Employees on forty-eight (48) hours written notice to Seller and Purchaser’s obligation to reimburse Seller
for future wages and related expenses with respect to such terminated Retained Employees shall end at the end of such 48 hour notice
period.

 

5.4 
Accounts Receivable. Promptly after the Closing, Seller shall deliver to Purchaser an updated schedule listing an accurate and complete breakdown
and aging of all accounts receivable, notes receivable and other receivables of the Seller as of the Closing Date.

 

5.5 
Non-Solicitation.

 

(a)               
Seller and Shareholder covenant that for a period of five (5) years following the Closing Date neither shall directly or
indirectly induce or seek to (i) influence any employee of the Purchaser or any of its affiliates to terminate his or her employment;
(ii) knowingly hire and/or aid a competitor of the Purchaser in hiring a current or former employee of the Purchaser; or (iii)
induce or seek to influence any Clients to reduce the volume of their business with Purchaser or not to do business with the Purchaser.

 

(b)              
Seller and Shareholder acknowledge that the restrictive period contained in Section 5.5(a) is reasonable under the circumstances.
Moreover, it is the desire and intent of the parties that the provisions of Section 5.54(a) be enforceable to the fullest extent
permissible under the legal requirements and public policies applied in each jurisdiction in which enforcement is sought. Seller
and Shareholder specifically agree that, in the event of a breach or threatened breach of Section 5.5(a), the Purchaser would suffer
irreparable injury and damages at law would be an insufficient remedy, and the Purchaser shall be entitled to seek equitable relief
by way of temporary or permanent injunction (or any other equitable remedies), without proof of actual damages and without the
need to post bond or other security.

 

5.6 
Change of Name. Immediately after the Closing, the Seller shall change its name to a name that is reasonably
satisfactory to Purchaser.

 

		6.	Miscellaneous Provisions.

 

6.1  Further
Assurances. Each party hereto shall execute and/or cause to be delivered to each other party hereto such instruments and other
documents, and shall take such other actions, as such other party may reasonably request (prior to, at or after the Closing) for
the purpose of carrying out or evidencing any of the Transactions.

 

    	 	A-23	 

     

    

6.2 
Sole Representations and Warranties. The Parties make no representations or
warranties of any kind or nature, express or implied, at law or in equity, except as expressly set forth in this Agreement or
in any certificate executed and delivered pursuant to this Agreement. Each Party hereby expressly negates and disclaims, and will
not be liable for, any and all representations or warranties which may have been made or alleged to have been made in any other
document or instrument or in any statement or information made or communicated to any other Party in any manner that is not expressly
set forth in this Agreement or any a certificate executed and delivered pursuant to this Agreement.

 

6.3 
Fees and Expenses. Each party shall be responsible for their respective fees and expenses incurred in connection
with the Transactions.

 

6.4  Notices.
Any notice or other communication required or permitted to be delivered to any party under this Agreement shall be in writing and
shall be deemed properly delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery
service or by facsimile) to the address or facsimile telephone number set forth beneath the name of such party below (or to such
other address or facsimile telephone number as such party shall have specified in a written notice given to the other parties hereto):

 

if to the Seller or Shareholders:

 

 

Rhonda Roberts-Turner

Address: 18302 Noyce
Road Crosby, Texas

Email:
Rhondaroberts@gulfcoastbilling.com

 

 

 

if to the Purchaser:

 

MTBC

7 Clyde Road

Somerset, NJ 08873

Attn: Amritpal Deol 

Facsimile: 732-964-9036

 

6.5  Headings.
The underlined headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of
this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement.

 

6.6  Counterparts.
This Agreement may be executed in several counterparts, each of which shall constitute an original and all of which, when taken
together, shall constitute one agreement.

 

6.7 
Unattached Exhibits. The parties acknowledge that certain exhibits and schedules to this Agreement to be prepared
by Seller or Purchaser have not been prepared or are incomplete at the time of execution of this Agreement. Seller and Purchaser
shall proceed with diligence and in good faith to prepare said exhibits and schedules and shall present same to the other party
for its review and approval. All exhibits and schedules so approved shall be initialed by each party and attached to this Agreement
prior to the Closing.

 

    	 	A-24	 

     

    

6.8 Remedies Cumulative; Specific
Performance. The rights and remedies of the parties hereto shall be cumulative (and not alternative) and Seller agrees that:
(a) in the event of any Breach or threatened Breach by Seller of any covenant, obligation or other provision set forth in this
Agreement, the Purchaser shall be entitled (in addition to any other remedy that may be available to it) to (i) a decree or
order of specific performance or mandamus to enforce the observance and performance of such covenant, obligation or other provision,
and (ii) an injunction restraining such Breach or threatened Breach; and (b) neither the Purchaser nor any other Indemnitee
shall be required to provide any bond or other security in connection with any such decree, order or injunction or in connection
with any related action or Proceeding.

 

6.9 
Waiver.

 

(a)               
No failure on the part of any Person to exercise any power, right, privilege or remedy under this Agreement, and no delay
on the part of any Person in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of
such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude
any other or further exercise thereof or of any other power, right, privilege or remedy.

 

(b)              
No Person shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy
under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument
duly executed and delivered on behalf of such Person; and any such waiver shall not be applicable or have any effect except in
the specific instance in which it is given.

 

6.10                     
Amendments. This Agreement may not be amended, modified, altered or supplemented other than by means of a written
instrument duly executed and delivered on behalf of the Purchaser and the Seller.

 

6.11                     
Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any
jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability
of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent
jurisdiction declares that any term or provision hereof is invalid or unenforceable, the parties hereto agree that the court making
such determination shall have the power to limit the term or provision, to delete specific words or phrases, or to replace any
invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing
the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified. In the
event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid
or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the
economic, business and other purposes of such invalid or unenforceable term.

 

    	 	A-25	 

     

    

6.12                     
Entire Agreement. The Transactional Agreements set forth the entire understanding of the parties relating to
the subject matter thereof and supersede all prior agreements and understandings among or between any of the parties relating to
the subject matter thereof.

 

6.13                     
Knowledge. For purposes of this Agreement, a Person shall be deemed to have “knowledge” of a particular
fact or other matter if any Representative of such Person has knowledge of such fact or other matter.

 

6.14                     
Construction.

 

(a)               
For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa;
the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter
genders; and the neuter gender shall include the masculine and feminine genders.

 

(b)              
The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting
party shall not be applied in the construction or interpretation of this Agreement.

 

(c)               
As used in this Agreement, the words “include” and “including,” and variations thereof, shall not
be deemed to be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.”

 

(d)              
Except as otherwise indicated, all references in this Agreement to “Sections” and “Exhibits” are
intended to refer to Sections of this Agreement and Exhibits to this Agreement.

 

6.15                     
Choice of Law and Venue. This Agreement shall be interpreted, construed and enforced in all respects in accordance
with the laws of the State of New Jersey, with the exception of its conflict of laws rules. The Parties will attempt to settle
any dispute, claim or controversy arising out of this Agreement through consultation and negotiation in good faith and in a spirit
of mutual cooperation. In the event of any dispute which the Parties cannot resolve between them through negotiation, the Parties
shall attempt to resolve the dispute through non-binding mediation. Parties shall select a mutually-acceptable mediator ten (10)
days after written notice by either Party demanding mediation with venue in the County of Somerset, New Jersey. Neither Party may
unreasonably withhold its consent to the selection of a mediator, and the Parties will share the costs of the mediation (or other
ADR) equally. ’By mutual agreement, however, the Parties may postpone mediation until each has completed some specified but
limited discovery about the dispute. The Parties may also agree to replace mediation with some other form of ADR, such as neutral
fact-finding or a minitrial. If the non-binding mediation or other agreed to ADR mechanism does not resolve the dispute, claim
or controversy arising out of this agreement, either Party may pursue or exhaust any remedy, including any legal or equitable relief.
Purchaser may place payments under the Transaction Agreement in an escrow account pending final resolution of any dispute.

 

    	 	A-26	 

     

    

The use of any ADR procedure will not be construed
under the doctrines of laches, waiver or estoppel to affect adversely the rights of either Party, and nothing in this Section 6.15
will prevent either Party from resorting to judicial proceedings if (1) good faith efforts to resolve the dispute under these procedures
have been unsuccessful, or (2) interim relief from a court is necessary to prevent irreparable injury to one Party or to others.

 

The parties to this Agreement have caused this
Agreement to be executed and delivered as of February 15, 2016.

 

	 	Gulf Coast Billing, Inc.	 
	 	a Texas Company	 
	 	 	 	 
	 	 	 	 
	 	By: 	/s/ Rhonda Roberts-Turner	 
	 	 	Rhonda Roberts-Turner, CEO	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	/s/ Rhonda Roberts-Turner	 
	 	Rhonda Roberts-Turner, Shareholder
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	Medical Transcription Billing, Corp.,
	 	  a Delaware corporation	 
	 	 	 	 
	 	 	 	 
	 	By: 	/s/ Stephen Snyder	 
	 	Name:   Stephen Snyder 	 
	 	Title:   President 	 

 

 

 

 

    	 	A-27	 

     

    

EXHIBIT A

 

CERTAIN DEFINITIONS

 

For purposes of the Agreement (including this
Exhibit “A”):

 

Acquisition Transaction. “Acquisition
Transaction” shall mean any transaction involving: (a) the sale or other disposition of all or any portion of the business
or assets of the Seller (other than in the Ordinary Course of Business); (b) the issuance, sale or other disposition of (i) any
capital stock or other securities of the Seller, (ii) any option, call, warrant or right (whether or not immediately exercisable)
to acquire any capital stock or other securities of the Seller, or (iii) any security, instrument or obligation that is or may
become convertible into or exchangeable for any capital stock or other securities of the Seller; or (c) any merger, consolidation,
business combination, share exchange, reorganization or similar transaction involving the Seller.

 

Adjustment. “Adjustment” shall mean
indemnification under Section 4 of this agreement and such expense reimbursements or reconciliation as are set forth in this Agreement.

 

Agreement. “Agreement” shall mean
the Asset Purchase Agreement to which this Exhibit “A” is attached (including the Disclosure Schedule),
as it may be amended from time to time.

 

Assumed Contracts. “Assumed Contracts”
shall mean all Medical Billing Agreements and all other Seller Contracts listed on Part 2.8 of the Disclosure Schedule unless identified
as an Excluded Asset on Exhibit “G”.

 

Assumed Liabilities. “Assumed Liabilities”
shall mean all obligations that accrue from and after March 1, 2016 relative to the Purchased Assets inclusive of the Assumed Contracts..

 

Best Efforts. “Best Efforts” shall
mean the commercially reasonable efforts that a prudent Person desiring to achieve a particular result would use in order to ensure
that such result is achieved as expeditiously as possible.

 

Breach. There shall be deemed to be a “Breach”
of a representation, warranty, covenant, obligation or other provision if there is or has been any inaccuracy in or breach (including
any inadvertent or innocent breach) of, or any failure (including any inadvertent failure) to comply with or perform, such representation,
warranty, covenant, obligation or other provision,; and the term “Breach” shall be deemed to refer to any such inaccuracy,
failure, claim or circumstance.

 

Business. “Business” shall have
the meaning ascribed thereto in the recital of this Agreement.

 

Client. “Client” shall mean each
Closing Date Client and each Pipeline Client.

 

Closing Date. “Closing Date” shall
mean February 15, 2016 12:01 A.M. EST.

 

    	 	A-28	 

     

    

Closing Date Clients. “Closing Date Clients”
shall mean those Persons listed on Exhibit “E” under the heading “Closing Date Clients” to
whom Seller is providing Medical Billing Services and remain in good standing on the Closing Date.

 

Code. “Code” shall mean the Internal
Revenue Code of 1986, as amended.

 

Consent. “Consent” shall mean any
approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).

 

Contract. “Contract” shall mean
any written, oral, implied or other agreement, contract, understanding, arrangement, instrument, note, guaranty, indemnity, representation,
warranty, deed, assignment, power of attorney, certificate, purchase order, work order, insurance policy, benefit plan, commitment,
covenant, assurance or undertaking of any nature.

 

Customer Data. “Customer Data” shall
mean all data maintained by or on behalf of Seller with respect to Seller’s Clients and the patients of such Clients, including
all Personal Data and health care records of such patients, and medical insurance coverage and provider information relating to
such patients.

 

Damages. “Damages” shall include
any loss, damage, injury, decline in value, lost opportunity, Liability, claim, demand, settlement, judgment, award, fine, penalty,
Tax, fee (including any legal fee, expert fee, accounting fee or advisory fee), charge, cost (including any cost of investigation)
or expense of any nature; but shall not include consequential damages or damages that are paid by any insurance policy.

 

Disclosure Schedule. “Disclosure Schedule”
shall mean the schedule (dated as of the date of the Agreement) delivered to the Purchaser on behalf of Seller, a copy of which
is attached to the Agreement and incorporated in the Agreement by reference.

 

Encumbrance. “Encumbrance” shall
mean any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance, equity, trust, equitable interest, claim,
preference, right of possession, lease, tenancy, license, encroachment, covenant, infringement, interference, Order, proxy, option,
right of first refusal, preemptive right, community property interest, legend, defect, impediment, exception, reservation, limitation,
impairment, imperfection of title, condition or restriction of any nature (including any restriction on the transfer of any asset,
any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction
on the possession, exercise or transfer of any other attribute of ownership of any asset).

 

Entity. “Entity” shall mean any
corporation (including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint
venture, estate, trust, cooperative, foundation, society, political party, union, company (including any limited liability company
or joint stock company), firm or other enterprise, association, organization or entity.

 

ERISA. “ERISA” shall mean the Employee
Retirement Income Security Act of 1974, as amended.

 

    	 	A-29	 

     

    

Excluded Assets. “Excluded Assets”
shall mean the assets identified on Exhibit “G”(to the extent owned by the Seller on the Closing Date).

 

Former Clients. “Former Client”
shall mean a Person (other than a Closing Date Client) to whom Seller has provided Medical Billing Services before the Closing
Date.

 

GAAP. “GAAP” shall mean generally
accepted accounting principles.

 

Governmental Authorization. “Governmental
Authorization” shall mean any: (a) permit, license, certificate, franchise, concession, approval, consent, ratification,
permission, clearance, confirmation, endorsement, waiver, certification, designation, rating, registration, qualification or authorization
issued, granted, given or otherwise made available by or under the authority of any Governmental Body or pursuant to any Legal
Requirement; or (b) right under any Contract with any Governmental Body.

 

Governmental Body. “Governmental Body”
shall mean any: (a) nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction
of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority
of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council,
board, instrumentality, officer, official, representative, organization, unit, body or Entity and any court or other tribunal);
(d) multi-national organization or body; or (e) individual, Entity or body exercising, or entitled to exercise, any executive,
legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.

 

Hazardous Material. “Hazardous Material”
shall include: (a) any petroleum, waste oil, crude oil, asbestos, urea formaldehyde or polychlorinated biphenyl; (b) any waste,
gas or other substance or material that is explosive or radioactive; (c) any “hazardous substance,” “pollutant,”
“contaminant,” “hazardous waste,” “regulated substance,” “hazardous chemical” or
“toxic chemical” as designated, listed or defined (whether expressly or by reference) in any statute, regulation or
other Legal Requirement (including CERCLA and any other so-called “superfund” or “superlien” law and the
respective regulations promulgated thereunder); (d) any other substance or material (regardless of physical form) or form of energy
that is subject to any Legal Requirement which regulates or establishes standards of conduct in connection with, or which otherwise
relates to, the protection of human health, plant life, animal life, natural resources, property or the enjoyment of life or property
from the presence in the environment of any solid, liquid, gas, odor, noise or form of energy; and (e) any compound, mixture, solution,
product or other substance or material that contains any substance or material referred to in clause “(a)”, “(b)”,
“(c)”or “(d)”above.

 

HIPAA. “HIPAA” shall mean the Health
Insurance Portability and Accountability Act of 1996, as amended.

 

Indemnitees. “Indemnitees” shall
mean the following Persons: (a) the Purchaser; (b) the Purchaser’s current and future affiliates; (c) the respective Representatives
of the Persons referred to in clauses “(a)”and “(b)”above; and (d) the respective successors and assigns
of the Persons referred to in clauses “(a)”, “(b)”and “(c)”above.

 

    	 	A-30	 

     

    

Initial Payment. “Initial Payment”shall
having the meaning ascribed thereto in section 1.2 hereof.

 

Installment Payment. “Installment Payment”
shall having the meaning ascribed thereto in section 1.2 hereof.

 

Intellectual Property. “Intellectual Property”
shall mean and include all internal billing processes, template appeals letters, algorithms, application programming interfaces,
apparatus, assay components, biological materials, cell lines, clinical data, chemical compositions or structures, circuit designs
and assemblies, databases and data collections, diagrams, formulae, gate arrays, IP cores, inventions (whether or not patentable),
know-how, logos, marks (including brand names, product names, logos, and slogans), methods, network configurations and architectures,
net lists, photomasks, processes, proprietary information, protocols, schematics, specifications, software, software code (in any
form including source code and executable or object code), subroutines, test results, test vectors, user interfaces, techniques,
URLs, web sites, works of authorship, and other forms of technology (whether or not embodied in any tangible form and including
all tangible embodiments of the foregoing such as instruction manuals, laboratory notebooks, prototypes, samples, studies, and
summaries).

 

Intellectual Property Rights. “Intellectual
Property Rights” shall mean and include all rights of the following types, which may exist or be created under the laws of
any jurisdiction in the world: (a) rights associated with works of authorship, including exclusive exploitation rights, copyrights,
moral rights, and mask works; (b) trademark and trade name rights and similar rights; (c) trade secret rights; (d) patents
and industrial property rights; (e) other proprietary rights in Intellectual Property of every kind and nature; and (f) all registrations,
renewals, extensions, continuations, divisions, or reissues of, and applications for, any of the rights referred to in clauses
(a) through (e) above.

 

IRS. “IRS” shall mean the United
States Internal Revenue Service.

 

Legal Requirement. “Legal Requirement”
shall mean any federal, state, local, municipal, foreign or other law, statute, legislation, constitution, principle of common
law, resolution, ordinance, code, edict, decree, proclamation, treaty, convention, rule, regulation, ruling, directive, pronouncement,
requirement, specification, determination, decision, opinion or interpretation issued, enacted, adopted, passed, approved, promulgated,
made, implemented or otherwise put into effect by or under the authority of any Governmental Body.

 

Liability. “Liability” shall mean
any debt, obligation, duty or liability of any nature (including any unknown, undisclosed, unmatured, unaccrued, unasserted, contingent,
indirect, conditional, implied, vicarious, derivative, joint, several or secondary liability), regardless of whether such debt,
obligation, duty or liability would be required to be disclosed on a balance sheet prepared in accordance with generally accepted
accounting principles and regardless of whether such debt, obligation, duty or liability is immediately due and payable.

 

Medical Billing Agreement. “Medical Billing
Agreement” shall mean each Contract pursuant to which the Seller provides Medical Billing Services to its Clients.

 

    	 	A-31	 

     

    

Medical Billing Services. “Medical Billing
Services” shall mean any and all actions relating to the management of a healthcare provider’s revenue cycle, including,
without limitation, enrollment, credentialing, claims submission, claims follow-up, collections, eligibility verification, patient
billing, revenue cycle analysis and consultation, together with the provision of related practice management services or products
including, without limitation, electronic medical record software, office scheduling software, transcription services, coding services,
medical collections and practice consultation.

 

Order. “Order” shall mean any: (a)
order, judgment, injunction, edict, decree, ruling, pronouncement, determination, decision, opinion, verdict, sentence, subpoena,
writ or award issued, made, entered, rendered or otherwise put into effect by or under the authority of any court, administrative
agency or other Governmental Body or any arbitrator or arbitration panel; or (b) Contract with any Governmental Body entered into
in connection with any Proceeding.

 

Ordinary Course of Business. An action taken
by or on behalf of the Seller shall not be deemed to have been taken in the “Ordinary Course of Business” unless:

 

(a)   such action is recurring in nature,
is consistent with the past practices of the Seller and is taken in the ordinary course of the normal day-to-day operations of
the Seller;

 

(b)   such action is taken in accordance
with sound and prudent business practices;

 

(c)   such action is not required to
be authorized by the Seller, the board of directors of the Seller or any committee of the board of directors of the Seller and
does not require any other separate or special authorization of any nature; and

 

(d)   such action is similar in nature
and magnitude to actions customarily taken, without any separate or special authorization, in the ordinary course of the normal
day-to-day operations of Entities in the business of providing Medical Billing Services.

 

Payor. “Payor” shall mean any health
maintenance organization, preferred provider organization, other prepaid plan, health care service plan, or worker’s compensation
or personal injury program or plan, including any Governmental Body under any Legal Requirement or any person acting on behalf
of a third party payor, responsible for making payments for healthcare products or services on behalf of another Person.

 

Parties. “Parties” shall mean, collectively,
Seller, Purchaser and Shareholder.

 

Person. “Person” shall mean any
individual, Entity or Governmental Body.

 

Personal Data. “Personal Data” shall
mean a natural person’s name, street address, telephone number, e-mail address, photograph, social security number, driver’s
license number, passport number, or customer or account number, or any other piece of information that allows the identification
of a natural person.

 

    	 	A-32	 

     

    

Pipeline Client. “Pipeline Client”
shall mean each prospective client listed on Exhibit “E” under the heading “Pipeline Clients.”

 

Proceeding. “Proceeding” shall mean
any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate
proceeding and any informal proceeding), prosecution, contest, hearing, inquiry, inquest, audit, examination or investigation commenced,
brought, conducted or heard by or before, or otherwise involving, any Governmental Body or any arbitrator or arbitration panel.

 

Purchased Assets. “Purchased Assets”
shall have the meaning set forth in Section 1.1, which is entitled “Purchase and Sale of the Purchased Assets.”

 

Registered IP. “Registered IP” shall
mean all Intellectual Property Rights that are registered, filed, or issued under the authority of any Governmental Body, including
all patents, registered copyrights, registered mask works, and registered trademarks and all applications for any of the foregoing.

 

Related Party. Each of the following shall be
deemed to be a “Related Party”: (a) each individual who is, or who has at any time been, an officer of the Seller;
(b) each member of the family of each of the individuals referred to in clause “(a)”above; and (c) any Entity (other
than the Seller) in which any one of the individuals referred to in clauses “(a)”and “(b)”above holds or
held (or in which more than one of such individuals collectively hold or held), beneficially or otherwise, a controlling interest
or a material voting, proprietary or equity interest.

 

Representatives. “Representatives”
shall mean officers, directors, managers, employees, agents, attorneys, accountants and advisors.

 

Seller Affiliate. “Seller Affiliate”
shall mean any Person under common control with the Seller within the meaning of Sections 414(b), (c), (m) and (o) of the Code,
and the regulations issued thereunder.

 

Seller Contract. “Seller Contract”
shall mean any Medical Billing Agreement and each other Contract: (a) to which the Seller is a party; (b) by which the
Seller or any of its assets is or may become bound or under which the Seller has, or may become subject to, any obligation; or
(c) under which the Seller has or may acquire any right or interest.

 

Seller Employee. “Seller Employee”
shall mean any current or former employee, independent contractor or director of the Seller or any Seller Affiliate.

 

Seller IP. “Seller IP” shall mean
(a) all Intellectual Property Rights in or pertaining to the Seller Products or methods or processes used or incorporated in the
Seller Products, and (b) all other Intellectual Property Rights owned by or exclusively licensed to the Seller.

 

Seller IP Contract. “Seller IP Contract”
shall mean any Contract to which the Seller is a party or by which the Seller is bound, that contains any assignment or license
of, or covenant not to assert or enforce, any Intellectual Property Right or that otherwise relates to any Seller IP or any Intellectual
Property developed by, with, or for the Seller.

 

    	 	A-33	 

     

    

Seller Product. “Seller Product”
shall mean any product or service designed, developed, marketed, distributed, provided, licensed, or sold at any time by the Seller.

 

Tax. “Tax” shall mean any tax (including
any income tax, franchise tax, capital gains tax, estimated tax, gross receipts tax, value-added tax, surtax, excise tax, ad valorem
tax, transfer tax, stamp tax, sales tax, use tax, property tax, business tax, occupation tax, inventory tax, occupancy tax, withholding
tax or payroll tax), levy, assessment, tariff, impost, imposition, toll, duty (including any customs duty), deficiency or fee,
and any related charge or amount (including any fine, penalty or interest), that is, has been or may in the future be (a) imposed,
assessed or collected by or under the authority of any Governmental Body, or (b) payable pursuant to any tax-sharing agreement
or similar Contract.

 

Tax Return. “Tax Return” shall mean
any return (including any information return), report, statement, declaration, estimate, schedule, notice, notification, form,
election, certificate or other document or information that is, has been or may in the future be filed with or submitted to, or
required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment, collection or
payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Legal Requirement
relating to any Tax.

 

Term. “Term” shall mean the period
commencing on February 15, 2016 and ending on March 1, 2019.

 

Transactional Agreements. “Transactional
Agreements” shall mean this Agreement, the bill of sale, assumption agreement and the other agreements that are executed
and delivered by the parties at the Closing.

 

Transactions. “Transactions” shall
mean (a) the execution and delivery of the respective Transactional Agreements, and (b) all of the transactions contemplated
by the respective Transactional Agreements, including: (i) the sale of the Purchased Assets by the Seller to the Purchaser in accordance
with the Agreement; (ii) the assumption of the Assumed Liabilities by the Purchaser pursuant to the Assumption Agreement; and (iii)
the performance by the Seller, and the Purchaser of their respective obligations under the Transactional Agreements, and the exercise
by the Seller and the Purchaser of their respective rights under the Transactional Agreements.

 

Transitional Costs. “Transitional Costs”
shall mean all costs incurred by Seller that are identified in Exhibit “J”.

 

 

 

 

 

 

 

 

A-34

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]